NewcelX Ltd. (NCEL)
$2.84-2.07%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1M
- Beta
- 0.93
- P/E (TTM)
- 8.61
- Short % float
- 2.17%
- Days to cover
- 1.6
- SI change
- -34.9%
- 1W
- -4.05%
- 1M
- -13.41%
- vs SPY 1W
- -3.92%
- vs SPY 1M
- -15.92%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 23
- GROWTH
- 43
- GARP
- 9
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC13.1%
REV YoY-
ROE21.8%
EPS YoY-
ROA14.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM8.61
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.75
P/FCF-
EV/EBITDA-0.25
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E6.49
ALTMAN Z-
CURR RATIO0.32
ND/EBITDA-
BETA0.93
Company news
FAQ
- What is LOPJLB’s current signal on NCEL?
- LOPJLB’s latest quantitative signal on NewcelX Ltd. (NCEL) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NCEL in?
- NewcelX Ltd. (NCEL) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does NewcelX Ltd. (NCEL) do?
- NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.